Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Clinical Drug Investigation|November 9, 2022
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D<sub>2</sub>-Based Pharmacological Class Effect Query Defined by FAERSSeth C Hopkins, Ajay Ogirala, Courtney Zeni, et al.
Biopharmaceutics & Drug Disposition|January 20, 2009
In vivo saturation binding of GABA-A receptor ligands to estimate receptor occupancy using liquid chromatography/tandem mass spectrometrySeth C Hopkins, J Brian Nofsinger, Michael S Allen, et al.
European Archives of Psychiatry and Clinical Neuroscience|May 10, 2023
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophreniaEric D Achtyes, Seth C Hopkins, Nina Dedic, et al.
Clinical Drug Investigation|February 16, 2026
Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting SystemSolomiya Gumenyuk, Ajay Ogirala, Steven T Szabo, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 22, 2021
Population pharmacokinetic analysis of ulotaront in subjects with schizophreniaGerald R Galluppi, Daniel G Polhamus, Jeannine M Fisher, et al.
Sleep Medicine|May 20, 2023
A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexySteven T Szabo, Seth C Hopkins, Robert Lew, et al.
Schizophrenia Bulletin Open|August 15, 2024
Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment StrategySeth C Hopkins, Sasagu Tomioka, Ajay Ogirala, et al.
Pharmacology Research & Perspectives|March 25, 2024
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophreniaGuangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, et al.
Journal of Clinical Pharmacology|July 6, 2026
How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and ImplementationBorje Darpo, Georg Ferber, Seth C Hopkins, et al.
Journal of Affective Disorders|October 6, 2021
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I DepressionAntony Loebel, Kenneth S Koblan, Joyce Tsai, et al.
Pageof 6